Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; … Read more
Poolbeg Pharma PLC (POLBF) - Total Liabilities
Latest total liabilities as of June 2025: $429.00K USD
Based on the latest financial reports, Poolbeg Pharma PLC (POLBF) has total liabilities worth $429.00K USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Poolbeg Pharma PLC - Total Liabilities Trend (2021–2024)
This chart illustrates how Poolbeg Pharma PLC's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Poolbeg Pharma PLC Competitors by Total Liabilities
The table below lists competitors of Poolbeg Pharma PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Software Aktiengesellschaft
PINK:SWDAF
|
USA | $907.90 Million |
|
Crystal Valley Financial Corp
PINK:CYVF
|
USA | $718.93 Million |
|
TTEC Holdings Inc
NASDAQ:TTEC
|
USA | $1.39 Billion |
|
Commercial Vehicle Group Inc
NASDAQ:CVGI
|
USA | $263.74 Million |
|
Bubs Australia Limited
PINK:BUBSF
|
USA | $14.69 Million |
|
Jayamas Medica Industri
JK:OMED
|
Indonesia | Rp390.05 Billion |
|
Muang Thai Insurance Public Company Limited
BK:MTI
|
Thailand | ฿20.16 Billion |
|
WRKR Ltd
AU:WRK
|
Australia | AU$53.25 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Poolbeg Pharma PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 24.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Poolbeg Pharma PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Poolbeg Pharma PLC (2021–2024)
The table below shows the annual total liabilities of Poolbeg Pharma PLC from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $974.00K | -1.22% |
| 2023-12-31 | $986.00K | +2.07% |
| 2022-12-31 | $966.00K | +120.55% |
| 2021-12-31 | $438.00K | -- |